TESARO Announces Successful Achievement of Primary and All Secondary Endpoints in Third and Final Phase 3 Trial of Rolapitant

[GlobeNewswire] – WALTHAM, Mass. — TESARO, Inc. , an oncology-focused biopharmaceutical company, today announced positive top-line results from the third and final Phase 3 trial of rolapitant, an investigational neurokinin-1 … more

View todays social media effects on TSRO

View the latest stocks trending across Twitter. Click to view dashboard

See who TESARO is hiring next, click here to view